A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma

Introduction: Current treatment options for BRAF V600-mutated unresectable stage III/IV melanoma include anti-PD-1 monotherapy or combination with anti-CTLA-4 or anti-LAG-3 agents, BRAF/MEK inhibitors, and clinical trials. The strategy of combination immunotherapy with nivolumab and ipilimumab has s...

Full description

Bibliographic Details
Main Authors: Dahlia Fedele, Stefano Moroso, Angelo Turoldo, Gabriele Bazzocchi, Claudio Conforti, Iris Zalaudek, Alessandra Guglielmi
Format: Article
Language:English
Published: Karger Publishers 2024-01-01
Series:Case Reports in Oncology
Subjects:
metastatic melanoma
immune checkpoint inhibitor
braf/mek inhibitor
Online Access:https://beta.karger.com/Article/FullText/535902

Internet

https://beta.karger.com/Article/FullText/535902

Similar Items